Logotype for Shionogi & Co Ltd

Shionogi & Co (4507) investor relations material

Shionogi & Co Q1 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Shionogi & Co Ltd
Q1 2026 earnings summary28 Jul, 2025

Executive summary

  • Achieved year-on-year growth in revenue and all profit metrics for Q1 FY2025, driven by expansion of the HIV franchise and increased royalty income, despite declines in domestic and overseas drug sales.

  • Operating profit rose 24.9% to ¥35.1B, profit attributable to owners increased 28.5% to ¥39.4B, and EBITDA grew 22.8% to ¥40.6B.

  • Comprehensive income decreased to ¥44.4B from ¥62.8B year-over-year, mainly due to lower other comprehensive income.

  • Integration of JT Group's pharmaceutical business and acquisition of Torii Pharmaceutical are progressing, with full absorption expected by December 2025.

  • Submitted regulatory applications for ensitrelvir in the US and Europe, supporting medium- to long-term growth.

Financial highlights

  • Revenue for Q1 FY2025 was ¥99.8B, up 2.2% year-over-year; gross profit increased to ¥87.5B; gross margin improved.

  • Basic EPS was ¥46.26, up from ¥36.02 year-over-year, reflecting a 3-for-1 stock split.

  • Cash and cash equivalents at quarter-end were ¥254.8B, down ¥120.0B from the previous quarter.

  • Cost of sales decreased due to changes in product mix; SG&A increased from US business expansion, while R&D expenses fell.

  • Finance income rose on higher dividends from ViiV, reflecting strong HIV franchise sales.

Outlook and guidance

  • H1 forecast is expected to be achieved, driven by continued HIV franchise and cefiderocol growth, increased Xocova sales from COVID-19, and ongoing cost management.

  • Full-year revenue forecast is ¥530.0B, up 20.9% year-over-year; operating profit forecast is ¥175.0B, up 11.7%.

  • No revisions to the previously announced consolidated financial forecast.

  • Strategic R&D investments and M&A activities are prioritized to accelerate growth.

  • Basic EPS for the year ending March 31, 2026 is projected at ¥211.59.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Shionogi & Co earnings date

Logotype for Shionogi & Co Ltd
Q2 202628 Oct, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Shionogi & Co earnings date

Logotype for Shionogi & Co Ltd
Q2 202628 Oct, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Shionogi & Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and marketing of a wide range of pharmaceutical products. The company's core business areas include prescription drugs, over-the-counter medications, and diagnostic products. Shionogi focuses on therapeutic areas such as infectious diseases, pain management, and cardiovascular diseases. It also provides contract development and manufacturing services to other pharmaceutical companies. Shionogi & Co., Ltd. is headquartered in Osaka, Japan, and its shares are listed on the TYO.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage